315 related articles for article (PubMed ID: 22687407)
1. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
4. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
5. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
7. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
9. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Fujii C; Imamura H; Fukunaga M; Kamigaki S; Kimura Y; Kawase T; Kawabata R; Fujino M; Iseki C; Hamaguchi Y; Yamamoto E; Ishizaka T; Hachino Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2457-9. PubMed ID: 24394143
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Hoesly FJ; Baker SG; Gunawardane ND; Cotliar JA
Arch Dermatol; 2011 Dec; 147(12):1418-23. PubMed ID: 22184763
[TBL] [Abstract][Full Text] [Related]
13. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
14. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
15. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
19. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]